Loading data for BLSM — first visit, this takes a few seconds.
BlossomHill Therapeutics, Inc.
22.41 +0.67 (3.08%)
- Market Cap
- $651.6M
- Volume
- 67.4K
- Dividend yield
- n/a
BlossomHill Therapeutics, Inc. (BLSM) Stock Price, Analysis & Data
Intrinsic Value
Analyst Forecast
Stock Forecasts →Latest Earnings
| Reported | Vs estimate | YoY Change | |
|---|---|---|---|
| Revenue | — | n/a | n/a |
| EPS | — | n/a | n/a |
Metrics
- Bid
- 21.5
- Market Cap
- 652M
- Revenue (ttm)
- n/a
- Net Income (ttm)
- -71.1M
- n/a
- -3.41
- n/a
- -6.03
- P/B (ttm)
- -0.39
- P/S (ttm)
- n/a
- Earnings Date
- n/a
- Ask
- 21.35
- Volume
- 67,363
- Avg. Volume (20D)
- 265,796
- Open
- 22.44
- Previous Close
- 21.74
- Day's Range
- 21.71 - 23.38
- 52-Week Range
- 15.25 - 23.38
- Analyst
- n/a
- Price Target
- n/a
- Dividends
- n/a
- Ex-Dividend Date
- n/a
About BlossomHill Therapeutics, Inc.
View profile →BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
Industry Biotechnology
Sector Healthcare
IPO Date Aug 7, 2026
Employees 63
Stock Exchange NasdaqGS
Ticker Symbol BLSM
Website https://bhtherapeutics.com